Crown Point, Ind.-based OYE Therapeutics has closed a $5 million convertible note financing round, oversubscribed to $5.6 million, to advance its intravenous caffeine-based therapy into clinical trials.
The treatments aim to “reverse general anesthesia, sedation and opioid-induced respiratory depression,” according to a Dec. 5 news release. Proceeds will support a phase 1 pharmacokinetic and safety study and future pivotal trials.
OYE plans to release clinical data in 2026. The company is headquartered at the Purdue Technology Center of Northwest Indiana.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.